| Name | T-1101 tosylate |
| Description | T-1101 tosylate (TAI-95 tosylate) is a Hec1/Nek2 inhibitor with antitumor activity. |
| Animal Research | SCID mice bearing human Huh-7, BT-474, MCF-7, and MDA-MB-231 xenografts. Dosage:25 mg/kg, 50 mg/kg. Oral administration; twice per day; 28 days |
| In vitro | T-1101 has good oral absorption, along with potent in?vitro antiproliferative activity (IC50: 14.8-21.5?nM). |
| In vivo | T-1101 tosylate can achieve high concentrations in Huh-7 and MDA-MB-231 tumor tissues, and showed promise in antitumor activity in mice bearing human tumor xenografts of liver cancer (Huh-7). |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 11 mg/mL (16.52 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3 mM), Sonication is recommended.
|
| Keywords | TAI-95 Tosylate | TAI95 Tosylate | TAI-95 | TAI95 | TAI 95 Tosylate | TAI 95 | T-1101 Tosylate | T1101 Tosylate | T-1101 | T1101 | T 1101 Tosylate | T 1101 | PPI | MicrotubuleAssociated | Microtubule Associated | Inhibitor | inhibit | Hec1/Nek2 | Hec1 | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Microtubule-Targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |